Greater Baltimore’s top NIH grant recipients include Johns Hopkins, Kennedy Krieger – Baltimore Business Journal

By | News | No Comments

Johns Hopkins University is again the top NIH grant recipient in Greater Baltimore in 2017, with a total grant value of $651.8 million last year.

The university also led all U.S. universities in research and development expenditures for the 38th consecutive year in fiscal year 2016, spending $2.4 billion on various research projects.

View Original Article »

Campus Director Leslie Weber Inducted As Chair of Montgomery County Chamber of Commerce – News – Johns Hopkins University Montgomery County Campus

By | News | No Comments

Leslie Weber was inducted in June as chair of the board of directors of the Montgomery County Chamber of Commerce. Weber is director of the Johns Hopkins University Montgomery County Campus and director of government and community affairs for Johns Hopkins in Montgomery County. She long has been involved with the Chamber: She has held leadership positions on the board and received the Chairman’s Award in 2016.

View Original Article »

gel-e expands its OTC label

By | News | No Comments

gel-e Inc., announces the 510(k) clearance of gel-e FLEX by the U.S. Food and Drug Administration (FDA) for the over-the-counter (OTC) use of its first flowable hemostat.

This new clearance expands the Company’s label that now includes the use of gels and bandages in the local management of bleeding, such as lacerations and minor bleeding. These products are specifically designed to create rapid hemostasis through easy-to-use applications for professional healthcare providers, parents, coaches, adult caregivers and even patients themselves. gel-e FLEX also complements the Company’s already FDA cleared vascular closure device, Vascular gel-e®, as it can be worn home by patients to manage any residual bleeding from an out-patient diagnostic or interventional procedure, see http://www.gel-e.co/products.html.

View Original Article »

CosmosID is the top performer in Janssen’s Mosaic Strain Challenge and precisionFDA’s CFSAN Pathogen Detection Challenge — CosmosID

By | News | No Comments

CosmosID a bioinformatics provider and NGS service laboratory announced that the company’s cloud-based bioinformatics platform for microbiome analysis has received the highest score in the strain-level microbial profiling category of the Mosaic Community Challenge and for strain-level microbial identification in the precisionFDA Pathogen Detection Challenge.

View Original Article »

Children’s National Hospital

By | Partners | No Comments

Children’s National Hospital, based in Washington, D.C., celebrates 150 years of pediatric care, research and commitment to community. Volunteers opened the hospital in 1870 with 12 beds for children displaced after the Civil War. Today, 150 years stronger, it is among the nation’s top 10 children’s hospitals. It is ranked No. 1 for newborn care for the fourth straight year and ranked in all specialties evaluated by U.S. News & World Report. Children’s National is transforming pediatric medicine for all children. In 2020, construction will be complete on the Children’s National Research & Innovation Campus, the first in the nation dedicated to pediatric research. Children’s National has been designated twice as a Magnet® hospital, demonstrating the highest standards of nursing and patient care delivery. This pediatric academic health system offers expert care through a convenient, community-based primary care network and specialty outpatient centers in the D.C., metropolitan area, including the Maryland and Northern Virginia suburbs. Children’s National is home to the Children’s National Research Institute and Sheikh Zayed Institute for Pediatric Surgical Innovation and is the nation’s seventh-highest NIH-funded children’s hospital. It is recognized for its expertise and innovation in pediatric care and as a strong voice for children through advocacy at the local, regional and national levels.

Emergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection

By | News | No Comments

Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 2 dose ranging study to evaluate the safety, pharmacokinetics, and clinical benefit of FLU-IGIV, the company’s anti-influenza immune globulin being developed as an intravenous treatment for serious illness caused by influenza A infection in hospitalized patients.

View Original Article »

Join our Mailing List